The Benign prostatic hyperplasia market report provides current treatment practices, emerging drugs, Benign prostatic hyperplasia (BPH) market share of the individual therapies, current and forecasted Benign prostatic hyperplasia (BPH) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current benign prostatic hyperplasia (BPH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Benign prostatic hyperplasia Overview
Benign prostatic hyperplasia (BPH) is a noncancerous condition in men in which the prostate gland is enlarged. BPH is also called benign prostatic hypertrophy or benign prostatic obstruction. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty when the prostate doubles in size. The second phase of growth begins around age 25 and continues during most of a man’s life. BPH often occurs with the second growth phase.
Download free sample copy- https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market
List of regions covered in the report
List of Benign Prostatic Hyperplasia companies involved in the report
Benign prostatic hyperplasia Cause
The cause of BPH is not well understood; however, it is most common in old men. As BPH does not develop in men whose testicles were removed before puberty, some researchers believe factors related to aging and the testicles are the underlying causes.
Benign prostatic hyperplasia Diagnosis
The diagnosis of BPH can be made by examining personal or family history, physical examination and medical tests. The American Urological Association (AUA) has built a BPH Symptom Score Index. It’s a series of questions about how often urinary symptoms happen. The score rates BPH from mild to severe.
Benign prostatic hyperplasia Treatment Market
The treatment of BPH includes lifestyle changes, medications, minimally invasive procedures, and surgery. It covers the details of conventional and current medical therapies available in the benign prostatic hyperplasia (BPH) market for the treatment of the condition. It also provides benign prostatic hyperplasia (BPH) treatment algorithms and guidelines in the United States, Europe, and Japan.
Benign prostatic hyperplasia Market Insight
The treatment of BPH includes watchful waiting, medical therapies, minimally invasive surgery, and surgery. Watchful waiting is the recommended strategy for patients with BPH who have mild symptoms and for those with moderate-to-severe symptoms who are not bothered by their symptoms and are not experiencing complications of BPH.
Benign prostatic hyperplasia Market Forecast
The smooth muscle tension is mediated by alpha-1-adrenergic receptors; hence, alpha-adrenergic receptor–blocking agents relax the smooth muscle, thus allowing easier passage of urine. Based on the receptor subtype selectivity and the duration of serum elimination half-lives, they are categorized into nonselective alpha-blockers (phenoxybenzamine), selective short-acting alpha-1 blockers (prazosin, alfuzosin, indoramin), selective long-acting alpha-1 blockers (terazosin, doxazosin, slow-release alfuzosin), and partially subtype (alpha-1a)–selective agents (tamsulosin (Flomax), silodosin (Rapaflo)).
Table of content
1. Key Insights
2. Executive Summary of Benign prostatic hyperplasia (BPH)
3. Competitive Intelligence Analysis for Benign prostatic hyperplasia (BPH)
4. Benign prostatic hyperplasia (BPH): Market Overview at a Glance
5. Benign prostatic hyperplasia (BPH): Disease Background and Overview
6. Patient Journey
7. Benign prostatic hyperplasia (BPH) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Benign prostatic hyperplasia (BPH) Treatment
11. Marketed Products
12. Emerging Therapies
13. Benign prostatic hyperplasia (BPH): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Benign prostatic hyperplasia (BPH)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Benign prostatic hyperplasia Market Report Highlights
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/